Next Article in Journal
Oligomerization of Silicic Acids in Neutral Aqueous Solution: A First-Principles Investigation
Previous Article in Journal
Comparative Genomics, Infectivity and Cytopathogenicity of American Isolates of Zika Virus that Developed Persistent Infections in Human Embryonic Kidney (HEK293) Cells
Previous Article in Special Issue
Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder
Open AccessReview

Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies

Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(12), 3036; https://doi.org/10.3390/ijms20123036
Received: 6 May 2019 / Revised: 7 June 2019 / Accepted: 18 June 2019 / Published: 21 June 2019
Molecular strategies tailored to promote/correct the expression and/or processing of defective coagulation factors would represent innovative therapeutic approaches beyond standard substitutive therapy. Here, we focus on the molecular mechanisms and determinants underlying innovative approaches acting at DNA, mRNA and protein levels in inherited coagulation factor deficiencies, and in particular on: (i) gene editing approaches, which have permitted intervention at the DNA level through the specific recognition, cleavage, repair/correction or activation of target sequences, even in mutated gene contexts; (ii) the rescue of altered pre-mRNA processing through the engineering of key spliceosome components able to promote correct exon recognition and, in turn, the synthesis and secretion of functional factors, as well as the effects on the splicing of missense changes affecting exonic splicing elements; this section includes antisense oligonucleotide- or siRNA-mediated approaches to down-regulate target genes; (iii) the rescue of protein synthesis/function through the induction of ribosome readthrough targeting nonsense variants or the correction of folding defects caused by amino acid substitutions. Overall, these approaches have shown the ability to rescue the expression and/or function of potentially therapeutic levels of coagulation factors in different disease models, thus supporting further studies in the future aimed at evaluating the clinical translatability of these new strategies. View Full-Text
Keywords: coagulation factor deficiencies; gene therapy; TALEs; CRISPR activation; RNA-based correction approaches; modified U1 snRNA; ribosome readthrough; chaperone-like compounds coagulation factor deficiencies; gene therapy; TALEs; CRISPR activation; RNA-based correction approaches; modified U1 snRNA; ribosome readthrough; chaperone-like compounds
Show Figures

Figure 1

MDPI and ACS Style

Balestra, D.; Branchini, A. Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies. Int. J. Mol. Sci. 2019, 20, 3036.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop